(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 48.59% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Trisalus Life Sciences's revenue in 2025 is $29,431,000.On average, 3 Wall Street analysts forecast TLSI's revenue for 2025 to be $1,429,540,977, with the lowest TLSI revenue forecast at $1,403,852,097, and the highest TLSI revenue forecast at $1,458,392,558. On average, 3 Wall Street analysts forecast TLSI's revenue for 2026 to be $2,135,242,903, with the lowest TLSI revenue forecast at $2,017,028,875, and the highest TLSI revenue forecast at $2,200,981,908.
In 2027, TLSI is forecast to generate $3,281,463,936 in revenue, with the lowest revenue forecast at $3,281,463,936 and the highest revenue forecast at $3,281,463,936.